Continuous monitoring skin temperature, through a wrist-worn device that records measurement during sleep, is more sensitive than basal body temperature (BBT) at detecting ovulation, according to a recent study.
Despite pre-existing chronic or terminal conditions in several patients presenting to the emergency department (ED) of a tertiary hospital in Singapore within hours or days of their demise, only a few have specified their preferences for end-of-life care, reveals a study.
The humanized immunoglobulin G1 monoclonal antibody risankizumab led to significant improvements in patients with active psoriatic arthritis (PsA), including those with insufficient response or intolerance to one or two biologic therapies or to at least one DMARD*, according to the results of the phase III KEEPsAKE2 trial presented at EULAR 2021.
Head-worn displays (HWDs) offer the possibility of continuous patient monitoring in critical care, reducing the risk of unrecognized deterioration, but severely lack strong evidence for its clinical benefit, according to a recent systematic analysis.
Only a small fraction of patients with stable ischaemic heart disease (SIHD) who undergo percutaneous coronary intervention (PCI) in the US meet the inclusion criteria of the ISCHEMIA* trial, according to results of a study presented at SCAI 2021.
Younger adults with chronic obstructive pulmonary disease (COPD) have excess risk of morbidity and mortality, contrary to common belief that the disease is mild at younger age, according to a longitudinal, population-base cohort study presented at the ATS 2021 Meeting.
Evaluating plasma kisspeptin levels, particularly during later gestational weeks of the first trimester of pregnancy, helps pinpoint women at risk of miscarriage, as shown in a study said to be the largest of its kind.
Insulin secretion is reduced in case of lesser low-density lipoprotein cholesterol (LDL-C), which possibly explains the deteriorated glycaemic control in response to cholesterol-lowering drugs, suggests a study.
New drug applications approved by US FDA as of 01-15 June 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.